Hunan Miso Biosciences Co., Ltd.

  According to WHO data, Currently, over 55 million people worldwide are afflicted with dementia, with more than 60% residing in low-income and middle-income countries. Nearly 10 million new cases emerge annually. This figure is projected to rise to 78 million people by the year 2030 and is expected to reach a staggering 139 million by the year 2050.   Recent researches show that CBD might be a potential solution to Alzheimer Disease Much research is ongoing worldwide to better understand the underlying causes of Alzheimer's and develop more effective treatments. There have been advancements in experimental drugs, immunotherapies, and other approaches that aim to modify the course of the disease, but none have resulted in a definitive cure at this point.   Cannabidiol (CBD) , a non-psychoactive compound found in the hemp plant, is emerging as a potential treatment option for Alzheimer's disease. While still in the early stages of research, several studies suggest that CBD may h

In the ever-evolving landscape of the CBD industry, selecting a reliable white label CBD partner is a critical decision for businesses operating in the rapidly growing CBD industry. The importance of this choice extends across various aspects of product development, brand reputation, and long-term success. Why do MiSo Bio so confident to be your white label partner? Reasons are here.  Advantage of World Factory China is famous for the World Factory. Located in China, MiSo Bio. leverages the full advantage of the "Made in China" ethos and advantages when it comes to customized white label solutions. This strategic positioning enables your businesses to access not only cost-effective manufacturing and rich material sources but also a wealth of expertise rooted in China's rich history of innovation and production prowess. China has established itself as a global manufacturing hub with a wealth of experience in various industries, including pharmaceuticals and natural product